The deaminated metabolite of gemcitabine, 2′,2′- difluorodeoxyuridine, modulates the rate of gemcitabine transport and intracellular phosphorylation via deoxycytidine kinase

Drug Metabolism and Disposition

Volumn 39, Issue 11, 2011, Pages 2013-2016

  Hodge, Lucy S ^a   Taub, Mitchell E ^b   Tracy, Timothy S ^a,c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^c University of Kentucky   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2',2' DIFLUORODEOXYURIDINE; DEOXYCYTIDINE KINASE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER; FLOXURIDINE DERIVATIVE; GEMCITABINE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DEAMINATION; DRUG DISPOSITION; DRUG METABOLISM; DRUG TRANSPORT; DRUG UPTAKE; HELA CELL; PHOSPHORYLATION; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; DEAMINATION; DEOXYCYTIDINE; DEOXYCYTIDINE KINASE; FLOXURIDINE; HELA CELLS; HUMANS; METABOLIC DETOXICATION, DRUG; PHOSPHORYLATION; POLYPHOSPHATES; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED;

EID: 80054748093     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.040790     Document Type: Article

References (16)

1. Bouffard DY, Laliberté J, and Momparler RL (1993) Kinetic studies on 2′,2′-difluorodeoxycytidine (gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase. Biochem Pharmacol 45:1857-1867.
2. Cass CE, King KM, Montaño JT, and Janowska-Wieczorek A (1992) A comparison of the abilities of nitrobenzylthioinosine, dilazep, and dipyridamole to protect human hematopoietic cells from 7-deazaadenosine (tubericidin). Cancer Res 52:5879-5886.
3. Endres CJ, Moss AM, Ke B, Govindarajan R, Choi DS, Messing RO, and Unadkat JD (2009) The role of equilibrative nucleoside transporter 1 (ENT1) in transport and metabolism of ribavirin by human and wild-type or Ent1(-/-) mouse erythrocytes. J Pharmacol Exp Ther 329:387-398.
4. Giusti G, Mangoni C, De Petrocellis B, and Scarano E (1970) Deoxycytidylate deaminase and deoxycytidine deaminase in normal and neoplastic tissues. Enzymol Biol Clin (Basel) 11:375-383.
5. Grunewald R, Abbruzzese JL, Tarassoff P, and Plunkett W (1991) Saturation of 2′,2′- difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol 27:258-262.
6. Hansen SW (2001) Gemcitabine in the treatment of ovarian cancer. Int J Gynecol Cancer 11:39-41.
7. Heinemann V (2005) Gemcitabine in metastatic breast cancer. Exp Rev Anticancer Ther 5:429-443.
8. Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB, and PlunkettW(1992) Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphate: a mechanism of self-potentiation. Cancer Res 52:533-539.
9. Hodge LS, Taub ME, and Tracy TS (2011) Effect of its deaminated metabolite, 2′,2′- difluorodeoxyuridine, on the transport and toxicity of gemcitabine in HeLa cells. Biochem Pharmacol 81:950-956.
10. Mackey JR, Mani RS, Selner M, Mowles D, Young JD, Belt JA, Crawford CR, and Cass CE (1998) Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 58:4349-4357. (Pubitemid 28450036)
11. Mackey JR, Yao SY, Smith KM, Karpinski E, Baldwin SA, Cass CE, and Young JD (1999) Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters. JNCI 91:1876-1881.
12. Mini E, Nobili S, Caciagli B, Landini I, and Mazzei T (2006) Cellular pharmacology of gemcitabine. Ann Oncol 17:v7-v12. (Pubitemid 43994854)
13. Plagemann PG, Woffendin C, Puziss MB, and Wohlhueter RM (1987) Purine and pyrimidine transport and permeation in human erythrocytes. Biochim Biophys Acta 905:17-29. (Pubitemid 18008573)
14. Plagemann PG, Wohlhueter RM, and Erbe J (1982) Nucleoside transport in human erythrocytes. A simple carrier with directional symmetry and differential mobility of loaded and empty carrier. J Biol Chem 257:12069-12074. (Pubitemid 13168900)
15. Symon Z, Davis M, McGinn CJ, Zalupski MM, and Lawrence TS (2002) Concurrent chemoradiotherapy with gemcitabine and cisplatin for pancreatic cancer: from the laboratory to the clinic. Int J Radiat Oncol Biol Phys 53:140-145. (Pubitemid 34465817)
16. Veltkamp SA, Pluim D, van Eijndhoven MA, Bolijn MJ, Ong FH, Govindarajan R, Unadkat JD, Beijnen JH, and Schellens JH (2008) New insights into the pharmacology and cytotoxicity of gemcitabine and 2′,2′- difluorodeoxyuridine. Mol Cancer Ther 7:2415-2425.